Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas

Abstract Soft tissue sarcomas (STS) are rare and heterogeneous tumours comprising over 80 different histological subtypes. Treatment options remain limited in advanced STS with high rates of recurrence following resection of localised disease. Prognostication in clinical practice relies predominantl...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eve Merry, Khin Thway, Robin L. Jones, Paul H. Huang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/124e621bfb764b3aaed8a52393b55b67
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:124e621bfb764b3aaed8a52393b55b67
record_format	dspace
spelling	oai:doaj.org-article:124e621bfb764b3aaed8a52393b55b672021-12-02T13:28:22ZPredictive and prognostic transcriptomic biomarkers in soft tissue sarcomas10.1038/s41698-021-00157-42397-768Xhttps://doaj.org/article/124e621bfb764b3aaed8a52393b55b672021-03-01T00:00:00Zhttps://doi.org/10.1038/s41698-021-00157-4https://doaj.org/toc/2397-768XAbstract Soft tissue sarcomas (STS) are rare and heterogeneous tumours comprising over 80 different histological subtypes. Treatment options remain limited in advanced STS with high rates of recurrence following resection of localised disease. Prognostication in clinical practice relies predominantly on histological grading systems as well as sarcoma nomograms. Rapid developments in gene expression profiling technologies presented opportunities for applications in sarcoma. Molecular profiling of sarcomas has improved our understanding of the cancer biology of these rare cancers and identified potential novel therapeutic targets. In particular, transcriptomic signatures could play a role in risk classification in sarcoma to aid prognostication. Unlike other solid and haematological malignancies, transcriptomic signatures have not yet reached routine clinical use in sarcomas. Herein, we evaluate early developments in gene expression profiling in sarcomas that laid the foundations for transcriptomic signature development. We discuss the development and clinical evaluation of key transcriptomic biomarker signatures in sarcomas, including Complexity INdex in SARComas (CINSARC), Genomic Grade Index, and hypoxia-associated signatures. Prospective validation of these transcriptomic signatures is required, and prospective trials are in progress to evaluate reliability for clinical application. We anticipate that integration of these gene expression signatures alongside existing prognosticators and other Omics methodologies, including proteomics and DNA methylation analysis, could improve the identification of ‘high-risk’ patients who would benefit from more aggressive or selective treatment strategies. Moving forward, the incorporation of these transcriptomic prognostication signatures in clinical practice will undoubtedly advance precision medicine in the routine clinical management of sarcoma patients.Eve MerryKhin ThwayRobin L. JonesPaul H. HuangNature PortfolioarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Precision Oncology, Vol 5, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Eve Merry Khin Thway Robin L. Jones Paul H. Huang Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas
description	Abstract Soft tissue sarcomas (STS) are rare and heterogeneous tumours comprising over 80 different histological subtypes. Treatment options remain limited in advanced STS with high rates of recurrence following resection of localised disease. Prognostication in clinical practice relies predominantly on histological grading systems as well as sarcoma nomograms. Rapid developments in gene expression profiling technologies presented opportunities for applications in sarcoma. Molecular profiling of sarcomas has improved our understanding of the cancer biology of these rare cancers and identified potential novel therapeutic targets. In particular, transcriptomic signatures could play a role in risk classification in sarcoma to aid prognostication. Unlike other solid and haematological malignancies, transcriptomic signatures have not yet reached routine clinical use in sarcomas. Herein, we evaluate early developments in gene expression profiling in sarcomas that laid the foundations for transcriptomic signature development. We discuss the development and clinical evaluation of key transcriptomic biomarker signatures in sarcomas, including Complexity INdex in SARComas (CINSARC), Genomic Grade Index, and hypoxia-associated signatures. Prospective validation of these transcriptomic signatures is required, and prospective trials are in progress to evaluate reliability for clinical application. We anticipate that integration of these gene expression signatures alongside existing prognosticators and other Omics methodologies, including proteomics and DNA methylation analysis, could improve the identification of ‘high-risk’ patients who would benefit from more aggressive or selective treatment strategies. Moving forward, the incorporation of these transcriptomic prognostication signatures in clinical practice will undoubtedly advance precision medicine in the routine clinical management of sarcoma patients.
format	article
author	Eve Merry Khin Thway Robin L. Jones Paul H. Huang
author_facet	Eve Merry Khin Thway Robin L. Jones Paul H. Huang
author_sort	Eve Merry
title	Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas
title_short	Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas
title_full	Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas
title_fullStr	Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas
title_full_unstemmed	Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas
title_sort	predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/124e621bfb764b3aaed8a52393b55b67
work_keys_str_mv	AT evemerry predictiveandprognostictranscriptomicbiomarkersinsofttissuesarcomas AT khinthway predictiveandprognostictranscriptomicbiomarkersinsofttissuesarcomas AT robinljones predictiveandprognostictranscriptomicbiomarkersinsofttissuesarcomas AT paulhhuang predictiveandprognostictranscriptomicbiomarkersinsofttissuesarcomas
_version_	1718392956719726592

Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas

Ejemplares similares